An experimental vaccine to cure SARS-CoV-2 was able to protect eight different rhesus macaque monkeys from the virus infection.

The “PiCoVacc” undergone the first trials of an inactivated coronavirus vaccine in rats, mice and monkeys.

Researchers actually infused SARS-CoV-2 virus into the monkeys’ lungs via tube into their tracheas and the medical team found out that not one monkey developed the full infection, says the trialsitenews.com

According to the report published by the biorxiv.org, these antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide.

The vaccine was invented by Sinovac Biotech Ltd, Beijing, China and their colleagues from the Chinese academy of sciences. Sinovac founded in 2001 is a biopharmaceutical company focusing on the development, manufacture and commercialization of vaccines that protect against human infectious diseases.

The company’s founders, including Mr. Weidong Yin, worked on vaccines at Tanghan Yian Biological Engineering Co. Ltd.

Sinoivac latest reports on their recently initiated Phase I clinical trial in Jiangsu province. Involving 144 volunteers, they seek to assess safety and immune response; they hope to initiate Phase II studies toward mid-May—with up to 1,000 participants.

Similar report published by the livescience.com, narrating that on the Twitter post of Florian Krammer, professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai dated on April 22, 2020, he said that this is the first serious preclinical data he has observed for an actual vaccine candidate.